A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl(Jazz Pharmaceuticals (United States)), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Deborah A. Thomas(Washington University in St. Louis), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Monica Kwari(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(Unknown), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center)
Cited by 201
Related Papers
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k